Galectin Therapeutics Культура компании

Dr. Peter G. Traber, M.D. has been the Chief Executive Officer and President of Galectin Therapeutics, Inc. since March 17, 2011 and serves as its Chief Medical Officer. Dr. Traber serves as the President Emeritus of Baylor College of Medicine. Dr. Traber served as an Acting Chief Medical Officer of Galectin Therapeutics, Inc. since June 15, 2010. Dr. Traber served as the President and Chief Executive Officer, Professor of Medicine at Baylor College of Medicine from March 2003 to November 2008. Dr. Traber served as Senior Vice President of Clinical Development & Medical Affairs and Chief Medical Officer at GlaxoSmithKline (GSK) Plc. Before joining GSK's predecessor, SmithKline Beecham, in September 2000, Dr. Traber served as the Chief Executive Officer of the University of Pennsylvania Health System in Philadelphia. He served as Interim Dean for the University of Pennsylvania School of Medicine since February 2000. He served as the Chairman of the Department of Internal Medicine at the University of Pennsylvania School from July 1997 to February 2000. He served as the Chief of Gastroenterology at the University of Pennsylvania School of Medicine from 1992 to 1997. He has been a Director of Caladrius Biosciences, Inc. since January 2015. He serves as a Director of Greater Houston Partnership. He served as a Director of Tanox Inc., since March 23, 2004 and Galectin Therapeutics, Inc. since February 12, 2009 until January 2018. He served as a Director of Houston Branch at Federal Reserve Bank Of Dallas. He served on the faculty at the University of Michigan School of Medicine in Ann Arbor from 1987 to 1992, where Dr. Traber helped build the research and clinical enterprise. Dr. Traber completed a fellowship in Gastroenterology Research at the University of Michigan Medical School and in 1997, he completed the Management Development Program for Physician Executives at The Wharton School at the University of Pennsylvania. Dr. Traber received his M.D. from Wayne State Medical School in Detroit in 1981 and completed a Residency in Internal Medicine at Northwestern University Medical School in Chicago, where he also did a Fellowship in Gastroenterology. He earned B.S. in chemical engineering from the University of Michigan.

Mr. Jack W. Callicutt, CPA has been the Chief Financial Officer of Galectin Therapeutics, Inc. since July 1, 2013. Mr. Callicutt served as the Chief Financial Officer of REACH Health, Inc. He served as Vice President of Finance at REACH Health, Inc. He served as the Chief Financial Officer and Vice President of Tikvah Therapeutics Inc. since August 6, 2007. He led the Therapeutics''s financial and administrative activities, including interaction with capital markets and investor relations. He served as Chief Financial Officer of Vystar Corporation from April 8, 2010 to August 12, 2011 and served as its Principal Accounting Officer. He served as a Consultant of VIA Pharmaceuticals Inc. He has over 18 years of public and private company experience and more than a decade of audit, tax and SEC registrant experience with a major audit firm. He served as Chief Financial Officer of IVOX and Coratus Genetics. He served as a Chief Financial Officer of VIA Pharmaceuticals Inc. until June 5, 2007. Mr. Callicutt served as the Senior Vice President of Corautus Genetics Inc. since January 1, 2007 and also served as its Chief Financial Officer since January 2006. He served as the Chief Accounting Officer and Assistant Secretary of Corautus Genetics Inc. since September 2003. and served as its Vice President, Finance and Administration from September 2003 to January 1, 2007. He joined Corautus Genetics Inc. in August 2003. Prior to Corautus, he spent 14 years with Deloitte & Touche, the last six years as an audit senior manager. He served on several board of non-profit organisations. He is active in community affairs such as the Atlanta Community Food Bank, Habitat for Humanity. Mr. Callicutt is a Certified Public Account and graduated cum laude with a BBA degree in Accounting and Computer science from Delta State University in 1989.

Dr. Eliezer Zomer, Ph.D. has been Vice President of Discovery Research and Product Development at Galectin Therapeutics, Inc., since March 9, 2017 and served as its Executive Director of Product Development since February 2, 2017 until March 9, 2017. Dr. Zomer served as Executive Vice President of Manufacturing & Product Development of Galectin Therapeutics, Inc. from 2000 to February 2, 2017. Dr. Zomer served as Vice President of Manufacturing and Product Development of Pro-Pharmaceuticals Inc. (AKA Galectin Therapeutics, Inc.) since May 1, 2002 and served as its Consultant since 2001. Before Pro Pharma, Dr. Zomer founded Alicon Biological Control, an Israeli company, where he served from November 2000 to July 2002; Vice President of Product Development at GlycoGenesys, Inc., (formerly SafeScience, Inc.) (Nasdaq SmallCap: GLGS) from December 1998 to July 2000; and as a Vice-President of Research and Development at Charm Sciences, Inc. from June 1987 to November 1998. Dr. Zomer served as a Member of Scientific Advisory Board of Pro-Pharmaceuticals Inc. Dr. Zomer received a B.Sc. Degree in Industrial Microbiology from the University of Tel Aviv in 1972, a Ph.D. in Biochemistry from the University of Massachusetts in 1978 and undertook post-doctoral study at the National Institutes of Health.

Dr. Harold H. Shlevin, Ph.D., has been Chief Operating Officer and Corporate Secretary of Galectin Therapeutics, Inc., since October 1, 2012. Dr. Shlevin was a Principal and Head of Bioscience Commercialization at Advanced Technology Development Center at Georgia Institute of Technology. He is a Biosciences Startup Catalyst at Advanced Technology Development Center. He is a 30-year bioscience-industry executive with broad senior management experience in medical devices, pharmaceuticals, diagnostics and vaccines. He has founded two startup companies. Dr. Shlevin served as Vice President of Product Commercial Development at Altea Therapeutics Corporation since May 2009. Dr. Shlevin served as the President and Chief Executive Officer of Tikvah Therapeutics Inc. since June 2006. He served as the Chief Executive Officer and President of Abbott Products, Inc. (also known as Solvay Pharmaceuticals Inc.) from June 2000 to January 2006. He served as Senior Vice President of Business Development and Scientific Affairs of Abbott Products, Inc. since August 1998. His past industry experience includes Senior Executive Positions at Bausch & Lomb Pharmaceuticals, G.D. Searle and Co., Ciba-Geigy Pharmaceuticals (now Novartis) and Ciba Vision and was a Founder of Ciba Vision Opthalmics. Dr. Shlevin served as the Chairman of Unimed Pharmaceuticals Inc. He serves as a Member of the Board of Solvay Draka. He serves as a Member of the Scientific Advisory Board at Clearside BioMedical, Inc. He serves as a Director of Unimed Pharmaceuticals Inc. Dr. Shlevin serves on the Board of Directors of the American Foundation for Suicide Prevention, the Board of Advisors of Morehouse School of Medicine and Board of Directors for the Georgia Biomedical Partnership.He served as a Director at Cardiome Pharma Corp. since October 14, 2004 until June 24, 2016. He served as a Director of Tikvah Therapeutics Inc. and Abbott Products, Inc. He served as an Assistant Professor of Pharmacology and Physiology at the Mayo Graduate School of Medicine, Mayo Foundation and Mayo Clinic. Dr. Shlevin served as a Director of the Pharmaceutical Research & Manufacturers of America, National Pharmaceutical Council. He is a member of the American Society of Pharmacology and Experimental Therapeutics, the American Physiological Society, the Biophysical Society, the Drug Information Association and the Licensing Executives Society. He holds Post-Doctoral degrees in Pharmacology and Physiology from the Mayo Graduate School of Medicine, Mayo Foundation and Mayo Clinic. Dr. Shlevin earned a Doctorate and Masters degree from University of Rochester Medical School and a Bachelor's degree from the Boston University.

Jack Callicutt serves as the CFO of Galectin Therapeutics Inc.. Jack started at Galectin Therapeutics Inc. in Jul of 2013. Jack currently resides in the Greater Atlanta Area.